Phase 4 N=716 A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With Chronic Migraine
Migraine Disorders
Primary: Change From Baseline in the Frequency of Headache Days — 22.0; -10.7 headache days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=148 Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Change From Baseline in HbA1c — -0.07; -0.87 percentage of HbA1c
Phase 4 N=81 Phenylephrine vs. Norepinephrine Infusion After Spinal Anesthesia for Cesarean Delivery
Effects of; Anesthesia, in Labor and Delivery
Primary: Number of Rescue Boluses to Maintain SBP — 25; 21 rescue boluses — p=0.12
Phase 4 N=30 Endotracheal Tube Holder and Bite Guard Research
Surgery · Anesthesia
Primary: Change in ETT Position — 3.4; 0.3 centimeters — p=<0.001
Phase 4 N=97 Brain Energy Metabolism in Individuals With Major Depressive Disorder Receiving Escitalopram
Depression
Primary: Responder and Remission Status (%), Based on the Depression Rating Scale Score — 36; 32 participants
Phase 4 N=687 Post Marketing Surveillance for ADACEL™ in South Korea
Diphtheria · Tetanus · Pertussis
Primary: Summary of Adverse Events Reported in Participants That Received a Single Intramuscular Dose of Adacel™ — 168; 1; 68 Participants
Phase 4 N=40 Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy
Inflammatory Bowel Disease
Primary: Complete Small Bowel Transit — 75; 95 percentage of subjects with passage
Phase 4 N=662 Regulatory Post-Marketing Surveillance Study for TETRAXIM™
Diphtheria · Tetanus · Pertussis
Primary: Number of Participants Reporting Unexpected Adverse Events Up 30 Days Following A Primary Series and Booster Injection of TETRAXIM™. — 76; 30; 10; 6 Participants
Phase 4 N=40 Brain GABA Levels and Treatment Response in Major Depressive Disorder
Major Depressive Disorder
Primary: Response and Remitter Status at Endpoint, Based on Change in Depression Severity Rating Scores — 16; 14 participants
Phase 4 N=339 Use of Metformin in Treatment of Childhood Obesity
Pediatric Obesity
Primary: Change in BMI and Percentage Fat Mass Standard Deviation Scores After One Year of Treatment With Metformin or Placebo — -0.370; -0.22; -0.139; -0.065 Z score
Phase 4 N=92 Trial to Optimize Mineral Outcomes in Dialysis Patients
Secondary Hyperparathyroidism · Chronic Kidney Disease
Primary: Percent of Patients Achieving Parathyroid Hormone Target ≤ 300 — 21 percentage of subjects meeting target — p=< 0.05
Phase 4 N=46 Study for Recalcitrant Age Related Macular Degeneration
Age Related Macular Degeneration
Primary: The Number of Patients With no Fluid on OCT — 10 participants
Phase 4 N=57 Possible Role of Chloroquine to Induce a Complete Remission in the Treatment of Autoimmune Hepatitis: a Randomized Trial
Autoimmune Hepatitis
Primary: Biochemical Response to Therapy — 14; 21 Participants
Phase 4 N=32 A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment
Breast Cancer
Primary: Progression-Free Survival (PFS) — 9.9 months
Phase 4 N=42 Pharmacological Treatment of Generalized Anxiety Disorder in the Elderly
Generalized Anxiety Disorder
Primary: Comparisons of End of Study HAM-A Score Means for Sertraline 50 mg vs Placebo, Sertraline 100 mg vs Placebo, and Sertraline 50 mg vs. Sertraline 100 mg — 10.638; 10.008…